Partial and Transient Clinical Response to Omalizumab in IL-21-Induced Low STAT3-Phosphorylation on Hyper-IgE Syndrome
Hyper-IgE syndrome (HIES) is a rare primary immunodeficiency characterized by elevated levels of immunoglobulin E (IgE), eczematous dermatitis, cold abscesses, and recurrent infections of the lung and skin caused by Staphylococcus aureus. The dominant form is characterized by nonimmunologic features...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-01-01
|
| Series: | Case Reports in Immunology |
| Online Access: | http://dx.doi.org/10.1155/2019/6357256 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850157786710671360 |
|---|---|
| author | Cesar Daniel Alonso-Bello María del Carmen Jiménez-Martínez María Eugenia Vargas-Camaño Sagrario Hierro-Orozco Mario Alberto Ynga-Durand Laura Berrón-Ruiz Julio César Alcántara-Montiel Leopoldo Santos-Argumedo Diana Andrea Herrera-Sánchez Fernando Lozano-Patiño María Isabel Castrejón-Vázquez |
| author_facet | Cesar Daniel Alonso-Bello María del Carmen Jiménez-Martínez María Eugenia Vargas-Camaño Sagrario Hierro-Orozco Mario Alberto Ynga-Durand Laura Berrón-Ruiz Julio César Alcántara-Montiel Leopoldo Santos-Argumedo Diana Andrea Herrera-Sánchez Fernando Lozano-Patiño María Isabel Castrejón-Vázquez |
| author_sort | Cesar Daniel Alonso-Bello |
| collection | DOAJ |
| description | Hyper-IgE syndrome (HIES) is a rare primary immunodeficiency characterized by elevated levels of immunoglobulin E (IgE), eczematous dermatitis, cold abscesses, and recurrent infections of the lung and skin caused by Staphylococcus aureus. The dominant form is characterized by nonimmunologic features including skeletal, connective tissue, and pulmonary abnormalities in addition to recurrent infections and eczema. Omalizumab is a humanized recombinant monoclonal antibody against IgE. Several studies reported clinical improvement with omalizumab in patients with severe atopic eczema with high serum IgE level. We present the case of a 37-year-old male with HIES and cutaneous manifestations, treated with humanized recombinant monoclonal antibodies efalizumab and omalizumab. After therapy for 4 years, we observed diminished eczema and serum IgE levels. |
| format | Article |
| id | doaj-art-2cadbd39d0894b31bf9865b9f3408921 |
| institution | OA Journals |
| issn | 2090-6609 2090-6617 |
| language | English |
| publishDate | 2019-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Immunology |
| spelling | doaj-art-2cadbd39d0894b31bf9865b9f34089212025-08-20T02:24:04ZengWileyCase Reports in Immunology2090-66092090-66172019-01-01201910.1155/2019/63572566357256Partial and Transient Clinical Response to Omalizumab in IL-21-Induced Low STAT3-Phosphorylation on Hyper-IgE SyndromeCesar Daniel Alonso-Bello0María del Carmen Jiménez-Martínez1María Eugenia Vargas-Camaño2Sagrario Hierro-Orozco3Mario Alberto Ynga-Durand4Laura Berrón-Ruiz5Julio César Alcántara-Montiel6Leopoldo Santos-Argumedo7Diana Andrea Herrera-Sánchez8Fernando Lozano-Patiño9María Isabel Castrejón-Vázquez10Immunology and Allergy Department, Centro Médico Nacional 20 de Noviembre, Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado, MexicoFaculty of Medicine, Universidad Nacional Autónoma de México, MexicoImmunology and Allergy Department, Centro Médico Nacional 20 de Noviembre, Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado, MexicoDermatology Department, Centro Médico Nacional 20 de Noviembre, Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado, MexicoUniversidad Nacional Autónoma de México, Facultad de Estudios Superiores Zaragoza, Facultad de Medicina, MexicoImmunodeficiencies Research Unit, Instituto Nacional de Pediatria, Secretaría de Salud, MexicoUniversidad Nacional Autónoma de México, Facultad de Estudios Superiores Zaragoza, Facultad de Medicina, MexicoDepartment of Molecular Biomedicine, CINVESTAV-IPN, MexicoImmunology and Allergy Department, Centro Médico Nacional 20 de Noviembre, Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado, MexicoImmunology and Allergy Department, Centro Médico Nacional 20 de Noviembre, Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado, MexicoImmunology and Allergy Department, Centro Médico Nacional 20 de Noviembre, Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado, MexicoHyper-IgE syndrome (HIES) is a rare primary immunodeficiency characterized by elevated levels of immunoglobulin E (IgE), eczematous dermatitis, cold abscesses, and recurrent infections of the lung and skin caused by Staphylococcus aureus. The dominant form is characterized by nonimmunologic features including skeletal, connective tissue, and pulmonary abnormalities in addition to recurrent infections and eczema. Omalizumab is a humanized recombinant monoclonal antibody against IgE. Several studies reported clinical improvement with omalizumab in patients with severe atopic eczema with high serum IgE level. We present the case of a 37-year-old male with HIES and cutaneous manifestations, treated with humanized recombinant monoclonal antibodies efalizumab and omalizumab. After therapy for 4 years, we observed diminished eczema and serum IgE levels.http://dx.doi.org/10.1155/2019/6357256 |
| spellingShingle | Cesar Daniel Alonso-Bello María del Carmen Jiménez-Martínez María Eugenia Vargas-Camaño Sagrario Hierro-Orozco Mario Alberto Ynga-Durand Laura Berrón-Ruiz Julio César Alcántara-Montiel Leopoldo Santos-Argumedo Diana Andrea Herrera-Sánchez Fernando Lozano-Patiño María Isabel Castrejón-Vázquez Partial and Transient Clinical Response to Omalizumab in IL-21-Induced Low STAT3-Phosphorylation on Hyper-IgE Syndrome Case Reports in Immunology |
| title | Partial and Transient Clinical Response to Omalizumab in IL-21-Induced Low STAT3-Phosphorylation on Hyper-IgE Syndrome |
| title_full | Partial and Transient Clinical Response to Omalizumab in IL-21-Induced Low STAT3-Phosphorylation on Hyper-IgE Syndrome |
| title_fullStr | Partial and Transient Clinical Response to Omalizumab in IL-21-Induced Low STAT3-Phosphorylation on Hyper-IgE Syndrome |
| title_full_unstemmed | Partial and Transient Clinical Response to Omalizumab in IL-21-Induced Low STAT3-Phosphorylation on Hyper-IgE Syndrome |
| title_short | Partial and Transient Clinical Response to Omalizumab in IL-21-Induced Low STAT3-Phosphorylation on Hyper-IgE Syndrome |
| title_sort | partial and transient clinical response to omalizumab in il 21 induced low stat3 phosphorylation on hyper ige syndrome |
| url | http://dx.doi.org/10.1155/2019/6357256 |
| work_keys_str_mv | AT cesardanielalonsobello partialandtransientclinicalresponsetoomalizumabinil21inducedlowstat3phosphorylationonhyperigesyndrome AT mariadelcarmenjimenezmartinez partialandtransientclinicalresponsetoomalizumabinil21inducedlowstat3phosphorylationonhyperigesyndrome AT mariaeugeniavargascamano partialandtransientclinicalresponsetoomalizumabinil21inducedlowstat3phosphorylationonhyperigesyndrome AT sagrariohierroorozco partialandtransientclinicalresponsetoomalizumabinil21inducedlowstat3phosphorylationonhyperigesyndrome AT marioalbertoyngadurand partialandtransientclinicalresponsetoomalizumabinil21inducedlowstat3phosphorylationonhyperigesyndrome AT lauraberronruiz partialandtransientclinicalresponsetoomalizumabinil21inducedlowstat3phosphorylationonhyperigesyndrome AT juliocesaralcantaramontiel partialandtransientclinicalresponsetoomalizumabinil21inducedlowstat3phosphorylationonhyperigesyndrome AT leopoldosantosargumedo partialandtransientclinicalresponsetoomalizumabinil21inducedlowstat3phosphorylationonhyperigesyndrome AT dianaandreaherrerasanchez partialandtransientclinicalresponsetoomalizumabinil21inducedlowstat3phosphorylationonhyperigesyndrome AT fernandolozanopatino partialandtransientclinicalresponsetoomalizumabinil21inducedlowstat3phosphorylationonhyperigesyndrome AT mariaisabelcastrejonvazquez partialandtransientclinicalresponsetoomalizumabinil21inducedlowstat3phosphorylationonhyperigesyndrome |